SLRX

NASDAQ

Salarius Pharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2015

News25/Ratings2

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

News · 26 weeks270%

2025-10-262026-04-19

Mix090d

No activity.

Latest news

25 items

104dSEC
SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.
DEF 14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
105dSEC
Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
106dPR
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Trading under DCOY to commence on January 8, 2026 Company's proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient 2026 plan features advancing lead antiviral into the clinic while expanding pipeline and partnership opportunities CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius) announces it will change its corporate name to Decoy Therapeutics Inc. (Decoy) and its common shares will trade on the Nasdaq Capital Market under the ticker symbol DCOY effective as of commencement of trading on January 8, 2026. These changes reflect the Company's focus
111dSEC
Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
111dINSIDER
Director Hanish Arnold C sold $17 worth of shares (27 units at $0.64), closing all direct ownership in the company (SEC Form 4)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
111dSEC
SEC Form 8-K filed by Salarius Pharmaceuticals Inc.
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
115dSEC
SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.
PRE 14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
125dSEC
SEC Form DEFA14A filed by Salarius Pharmaceuticals Inc.
DEFA14A - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
125dSEC
Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
125dPR
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) ("Salarius" or the "Company") today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on December 19, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on November 7, 2025. The required quorum for the transaction of business at the Annual Meeting is 34% of the outstanding shares entitled to vote. There was less than the required voting power represented in perso
126dPR
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker "DCOY" effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker sy
143dPR
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Salarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting potential for anti-flu activity IMP3ACT's demonstrated capability to create a single antiviral therapeutic against influenza, COVID and RSV has potential to position Salarius to address large existing global commercial opportunity CAMBRIDGE, Mass. and HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a preclinical biopharmaceutical subsidiary of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) that is engineering the next generation of peptide conjugate thera
150dINSIDER
Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
154dINSIDER
Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
155dSEC
Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
155dPR
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX"
HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock continues to trade uninterrupted on the Nasdaq Stock Market under the stock ticker "SLRX." S&P CapIQ inaccurately characterized the Salarius Pharmaceuticals and Decoy Therapeutics merger and inaccurately stated that the Company had been delisted from the Nasdaq Capital Market. The Company is working to have this inaccurate information corrected. Similar inaccuracies that appeared on Yahoo Finance were corrected earlier this week. On November 13, 2025, Salarius completed an under
156dSEC
SEC Form SCHEDULE 13G filed by Salarius Pharmaceuticals Inc.
SCHEDULE 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
157dSEC
Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
160dSEC
SEC Form 10-Q filed by Salarius Pharmaceuticals Inc.
10-Q - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
161dSEC
Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
161dPR
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Strategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company has pro forma cash of $14 million following merger and closing of recent public offering HOUSTON and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals (NASDAQ:SLRX) ("Salarius" or the "Company") and Decoy Therapeutics ("Decoy") announce the completion of their strategic merger with the combined company now focused on advancing Decoy's pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and m
162dPR
Strong Earnings and Biotech Resilience Define the Midweek Momentum
DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB:KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe, Kraig Biocraft Laboratories (OTCQB:KBLB) appears poised to crack biotechnology's most persistent challenge: scalable, high-performance recombinant spider silk. Kraig's imminent shipments of spider silk fiber and fabric samples to fashion and performance textile partners signal a watershed moment. Unlike fermentation-based methods that have frustrated even DuPont, BASF, and Bolt Threads, Kraig's innovation lies in reprogramming silkworms themselves to spi
162dSEC
SEC Form 424B4 filed by Salarius Pharmaceuticals Inc.
424B4 - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
163dPR
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
HOUSTON, Nov. 11, 2025 /PRNewswire/ -- Salarius Pharmaceuticals, Inc. ("Salarius" or the "Company") (NASDAQ:SLRX) today announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting discounts and commissions and other offering expenses. The offering is comprised of 2,514,335 shares of its common stock ("Common Stock") and pre-funded warrants to purchase 2,152,331 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to an aggregate of 4,666,666 shares of Common Stock and Series B Warrants to purchase up to an aggregate of 4,666,666 shares of Common Stock. The combined public offering pr
164dSEC
SEC Form FWP filed by Salarius Pharmaceuticals Inc.
FWP - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)